We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
QARZIBA (Emerge Health Pty Ltd)
Product name
QARZIBA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
137 working days (255)
Active ingredients
dinutuximab beta
Registration type
NCE/NBE
Indication
QARZIBA (concentrated solution for injection) is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response.
Registration process
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.